{
  "docId": "019de070-fbaf-759b-8cbd-9f18172b1352",
  "docSlug": "7d8ead18d80cb869cda17e33a74aeb0b",
  "documentTitle": "BioNTech | Results Presentation Deck | 30 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 30,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "propose_solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "Includes a process flow diagram and a bar chart showing cytokine response.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-fbaf-759b-8cbd-9f18172b1352/21",
  "deckHref": "/decks/019de070-fbaf-759b-8cbd-9f18172b1352",
  "deckJsonHref": "/decks/019de070-fbaf-759b-8cbd-9f18172b1352.json",
  "deckAnchorHref": "/decks/019de070-fbaf-759b-8cbd-9f18172b1352#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.32,
        "x": 0.63,
        "y": 0.215
      },
      "kind": "chart",
      "text": "BNT221 cells specifically recognize autologous tumor",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d944b5b9-8fd3-43fb-92dc-e0b4a94aa85a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.65,
        "x": 0.04,
        "y": 0.68
      },
      "kind": "diagram",
      "text": "Process flow from Tumor Sample & Sequencing to BNT221 Personal Neoantigen T cell Therapy",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e0b65cd-ec9c-45d5-848a-c4c96ddd6ed4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.55,
        "x": 0.04,
        "y": 0.215
      },
      "kind": "list",
      "text": "Addresses limitations of TIL cell therapy approaches: T cells induced from peripheral blood (NEO-STIM), No gene engineering or viral vectors, Targets each patient's personal tumor neoantigens, Multiple specific CD8+ and CD4+ T cell populations, First patient dosed in Phase 1 trial",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2de7e64b-31aa-46c3-b8df-e48459f725c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.04,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "TIL, tumor-infiltrating lymphocyte; Lenkala D, et al. J Immunother Cancer 2020; 8(Suppl 3) A153",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cb483d9c-2cda-4ed6-a4c2-16a106c4d31c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.04,
        "y": 0.09
      },
      "kind": "title",
      "text": "BNT221: NEO-STIM® Personalized Neoantigen-Targeted Adoptive Cell Therapy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d71d5d3-9c69-4688-a518-d37af04b8e4e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "7c3ff4b2-1402-402a-81f4-6c1f6972a654",
      "evidence": "list/bullet: Addresses limitations of TIL cell therapy approaches: T cells induced from peripheral blood (NEO-STIM), No gene engineering or viral vectors, Targets each patient's personal tumor neoantigens, Multiple speci",
      "confidence": 0.7
    },
    {
      "name": "Process flow",
      "slug": "process-flow",
      "agent": null,
      "layer": "slide",
      "matchId": "cbbbf4b1-3b1c-4b0b-b1a4-e34d2e6f2ddf",
      "evidence": "diagram/process: Process flow from Tumor Sample & Sequencing to BNT221 Personal Neoantigen T cell Therapy",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "3a9c34c2-c4b2-426d-8012-4cb56d261d7c",
      "evidence": "Process flow diagram at bottom of slide",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 30,
      "from": 17,
      "beatId": "b630b8e9-6492-4b4d-a542-b4aa7c3b986e",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The deck concludes with financial results, global footprint, and pipeline milestones",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 24,
      "from": 17,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "3e964042-540f-49d8-932e-54e5cecf05d0",
      "evidence": "The deck highlights the company's progress on COVID-19 vaccine deliveries and revenue growth",
      "position": 1,
      "objective": "The consequences of not acting on COVID-19 vaccine strategy",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.5,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}